Evidence map›Paper›PMID 38411775›Full record

ArticleInflammation2024

Quercetin Regulates Microglia M1/M2 Polarization and Alleviates Retinal Inflammation via ERK/STAT3 Pathway.

Yue Zou, Junliang Jiang, Yunqin Li, Xinyi Ding, Fang Fang, Ling Chen

Abstract read
PubMed Publisher
In one paragraph

Article in Inflammation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 27 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Review
  8. Review
  9. (Ba,Ca)(Ti,Sn)OFrontiers in cellular neuroscience · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
  15. Frontiers in pharmacology · 2025
    Review
  16. Review
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Yue Zou *Eye Institute and Department of Ophthalmology, Eye & ENT Hospital, China NHC Key Laboratory of Myopia (Fudan University) Key Laboratory of Myopia Chinese Academy of Medical Sciences, Fudan University, 83 Fenyang Road, Xuhui District, Shanghai, 200031, China.
Junliang Jiang *Department of Orthopedics & Traumatology, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Yunqin Li *Yunnan Eye Institute & Key Laboratory of Yunnan Province, Yunnan Eye Disease Clinical Medical Center, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Xinyi DingEye Institute and Department of Ophthalmology, Eye & ENT Hospital, China NHC Key Laboratory of Myopia (Fudan University) Key Laboratory of Myopia Chinese Academy of Medical Sciences, Fudan University, 83 Fenyang Road, Xuhui District, Shanghai, 200031, China.
Fang FangYunnan Eye Institute & Key Laboratory of Yunnan Province, Yunnan Eye Disease Clinical Medical Center, Affiliated Hospital of Yunnan University, Yunnan University, Kunming, China.
Ling ChenEye Institute and Department of Ophthalmology, Eye & ENT Hospital, China NHC Key Laboratory of Myopia (Fudan University) Key Laboratory of Myopia Chinese Academy of Medical Sciences, Fudan University, 83 Fenyang Road, Xuhui District, Shanghai, 200031, China. linglingchen98@hotmail.com.
Yunnan University · CNEye & ENT Hospital of Fudan University · CN

Funding

National Natural Science Foundation of China 81371042Science and Technology Innovation Action Plan of Shanghai Science and Technology Commission 22Y11910500Yunnan Provincial Department of Science and Technology - Kunming Medical University Joint Fund for Applied Basic Research 202301AY070001-086Yunnan Provincial Education Department's Scientific Research Foundation 2023J0039Yunnan Provincial Young and Middle - Aged Academic and Technical Leaders Reserve Talents Project 202305AC160073
6 · The paper itself

Abstract

Retinal inflammation is a pivotal characteristic observed in various retinal degenerative disorders, notably age-related macular degeneration (AMD), primarily orchestrated by the activation of microglia. Targeting the inhibition of microglial activation has emerged as a therapeutic focal point. Quercetin (Qu), ubiquitously present in dietary sources and tea, has garnered attention for its anti-neuroinflammatory properties. However, the impact of Qu on retinal inflammation and the associated mechanistic pathways remains incompletely elucidated. In this study, retinal inflammation was induced in adult male C57BL/6 J mice through intraperitoneal administration of LPS. The results revealed that Qu pre-treatment induces a phenotypic shift in microglia from M1 phenotype to M2 phenotype. Furthermore, Qu attenuated retinal inflammation and stabilized the integrity of the blood-retina barrier (BRB). In vitro experiments revealed that Qu impedes microglial activation, proliferation, and migration, primarily via modulation the ERK/STAT3 signaling pathway. Notably, these actions of Qu significantly contributed to the preservation of photoreceptors. Consequently, Qu pre-treatment holds promise as an effective strategy for controlling retinal inflammation and preserving visual function.

Indexed as

Mice, Inbred C57BLMicrogliaQuercetinSTAT3 Transcription FactorAnimalsAnti-Inflammatory AgentsBlood-Retinal BarrierInflammationLipopolysaccharidesMaleMAP Kinase Signaling SystemMiceRetinaRetinitisAnti-Inflammatory AgentsLipopolysaccharidesQuercetinStat3 protein, mouseSTAT3 Transcription Factorage-related macular degeneration.microgliaquercetinretinainflammation

Identifiers

PMID38411775
OpenAlexW4392200160

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.